WAY-100635 Maleate|cas:1092679-51-0|西域试剂

WAY-100635 Maleate,99.89%

产品编号：Bellancom-10349A| CAS NO：1092679-51-0| 分子式：C₂₉H₃₈N₄O₆| 分子量：538.64

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-10349A	￥900.00	杭州北京（现货）
Bellancom-10349A	￥1200.00	杭州北京（现货）
Bellancom-10349A	￥4200.00	杭州北京（现货）
Bellancom-10349A	￥7200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

WAY-100635 Maleate

产品介绍

WAY-100635 maleate 是一种有效且具有选择性的 5-hydroxytryptamine 1A (5-HT1A) 受体拮抗剂，其 IC₅₀ 值为 0.91 nM，K_i 值为 0.39 nM。WAY-100635 maleate 对于 5-HT1A 和 α1-肾上腺素的 pIC₅₀ 值分别为 8.9 和 6.6。WAY-100635 maleate 也是一种有效的多巴胺 D₄ 受体激动剂。

生物活性

WAY-100635 maleate is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC₅₀ value of 0.91 nM and K_i value of 0.39 nM. WAY-100635 maleate has pIC₅₀ values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent dopamine D₄ receptor agonist.

体外研究

The functional properties and binding affinities of WAY-100635 are evaluated in HEK 293 cells stably expressing dopamine D_2L or D_4.4 receptors.
WAY-100635 displays 940, 370, and 16 nM binding affinities at D_2L, D₃, and D_4.2 receptors, respectively. Saturation analyses demonstrat that the K_d of [³H] WAY-100635 at D_4.2 receptors is 2.4 nM. WAY-100635 is potent agonist in HEK-D_4.4 cells with EC₅₀ of 9.7 nM. WAY-100635 possesses high affinity for D_4.4 receptor (3.3 nM) .

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

WAY-100635 (1 mg/kg; subcutaneous injection; male Sprague-Dawley rats) treatment abolishes the reduction of the severity of abstinence signs induced by Rhodiola rosea administration in nicotine-dependent rat.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (220-240 g)
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (Pharmacokinetic study)
Result:	Reduced total abstinence score, increased immobility time and the burying behavior was increased.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (220-240 g)
Dosage:	1 mg/kg
Administration:	Subcutaneous injection (Pharmacokinetic study)
Result:	Reduced total abstinence score, increased immobility time and the burying behavior was increased.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 250 mg/mL (464.13 mM)

H₂O : 25 mg/mL (46.41 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8565 mL	9.2826 mL	18.5653 mL
5 mM	0.3713 mL	1.8565 mL	3.7131 mL
10 mM	0.1857 mL	0.9283 mL	1.8565 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶